Our proprietary antibody development platform integrates innovative antigen presentation and advanced screening technologies to accelerate the discovery of high-performance monoclonal antibodies (mAbs). Initially, target antigens are either expressed in our proprietary mouse cell lines or conjugated to mouse spleen cells using our unique conjugation technology. These antigen-presenting cells are then used to immunize fully humanized antibody mice, enabling the generation of a diverse and human-relevant immune response. Antibody candidates are subsequently identified through either conventional hybridoma technology or cutting-edge single B-cell sequencing. The resulting mAbs undergo rigorous multi-step screening assays to evaluate binding specificity, affinity, and functional activity, ensuring selection of the most potent and therapeutically relevant candidates.